MFS
KLRS

Mirabella Financial Services’s Kalaris Therapeutics KLRS Stock Holding History

Mirabella Financial Services’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-730
Closed -$462K – 511
2020
Q3 		$462K Buy
+730
New +$499K 0.06% 151

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Mirabella Financial Services's KLRS Position: Q4 2020 in Review

Mirabella Financial Services sold out of Kalaris Therapeutics (KLRS) in Q4 2020, closing a stake of 730 shares — an estimated $462K sold.

Mirabella Financial Services first reported a position in KLRS in Q3 2020 and held it in 1 quarter. The position peaked at $462K in Q3 2020. 71 funds tracked by Wall St. Rank hold KLRS as of Q4 2020.

  • Mirabella Financial Services reported no remaining Kalaris Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Mirabella Financial Services sold 730 Kalaris Therapeutics shares in Q4 2020, an estimated $462K.
  • Mirabella Financial Services first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 1 quarter.
  • Mirabella Financial Services's Kalaris Therapeutics position peaked at $462K in Q3 2020.
  • 71 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2020.

Based on Mirabella Financial Services's 13F filing for Q4 2020, filed 16 Feb 2021.